Physician profile
Robert Mcclure
NPI 1386600906
$33,339.49
in general payments reported to CMS, 2019-2025
29 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $577 · 2021: $5,081 · 2022: $11K · 2023: $3,750 · 2024: $1,122 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,219.03 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $735.98 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $450.97 | 2020-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $442.92 | 2019-2025 | Stelara, Simponi Aria, Tremfya |
| Madrigal Pharmaceuticals | $429.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $362.34 | 2021-2023 | Ocaliva |
| Pfizer INC. | $309.75 | 2019-2025 | |
| Genzyme Corporation | $187.82 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $187.27 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $185.80 | 2019-2024 | Injectafer |
| Aimmune Therapeutics, INC. | $134.46 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $87.19 | 2019-2024 | |
| Celgene Corporation | $78.27 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $68.60 | 2023-2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $65.94 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $63.36 | 2019 | |
| Allergan, INC. | $57.30 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $50.27 | 2023 | Rebyota |
| Alfasigma USA, INC. | $36.78 | 2020-2021 | |
| Medtronic, INC. | $35.28 | 2024-2025 | Gi Genius, Endoflip |
| Qol Medical, LLC | $27.48 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $24.54 | 2025 | |
| Evoke Pharma, INC. | $19.86 | 2023 | Gimoti |
| Astrazeneca Pharmaceuticals LP | $16.85 | 2023 | Airsupra |
| Lilly USA, LLC | $16.42 | 2023 | |
| Covidien LP | $15.90 | 2020 | |
| Redhill Biopharma INC. | $15.03 | 2020 | |
| Ambu INC. | $10.88 | 2021 | |
| Phathom Pharmaceuticals, INC. | $4.11 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.